Conferences
ESMO 2024: Histology Subtypes (variants) of Bladder Cancer
September 16, 2024
ESMO 2024: Health-Related Quality of Life from the CheckMate 901 Trial of Nivolumab as First-Line Therapy for Unresectable or Metastatic Urothelial Carcinoma
September 16, 2024
ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304)
September 16, 2024
ESMO 2024: Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy
September 16, 2024
ESMO 2024: A New Prognostic Model of Overall Survival (OS) in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
September 16, 2024
ESMO 2024: Hematologic Impact of [177Lu]Lu-PSMA-617 Versus ARPI Change in Patients with Metastatic Castration-Resistant Prostate Cancer in PSMAfore
September 16, 2024
ESMO 2024: Targeting Epigenetic Pathways
September 16, 2024
ESMO 2024: Invited Discussant: CC-94676-PCA-001 and INSPIRE
September 16, 2024